Thursday, 7 March 2019

Are feminine hygiene products safe or they too contain toxic elements?

The global feminine hygiene product market size is anticipated to reach USD 33.78 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 6.5% over the forecast period. The growth is catapulted by rise in disposable income, awareness among women regarding the available solutions, and commercialization of innovative and eco-friendly products. Initiatives by companies, government agencies, and self-help groups have resulted in raising awareness among women about various menstrual hygiene and sanitary products.

WaterAid, an international nonprofit organization, released a series of short films titled If Men Had Periods to raise awareness about lack of access to washrooms during menstruation for the global female population. Websites such as Menstrupedia and Wash United coupled with commercials, social media marketing campaigns, and awareness initiatives are expected to be lucrative for market growth in near future.
Asia Pacific held the largest market share in terms of revenue owing to the presence of a large female population and rise in disposable income. North America also constituted for a significant market share in terms of revenue due to availability of diverse products and high consumer awareness. Demand for innovative products such as menstrual cups and period panties is anticipated to further propel growth of the regional market.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the study suggest:
  • The menstrual care products segment, which consists of sanitary napkins, tampons, and menstrual cups, continue to hold the largest market share in terms of revenue. Repeated purchase and ease of usage are anticipated to drive the product demand
  • Supermarkets is anticipated to remain the highest gaining distribution channel in the feminine hygiene product market over the forecast period. Availability of a diverse product range and easy accessibility are projected to propel the segment growth
  • With the boom in e-commerce, online retail store segment is expected to gain a significant market share in near future
  • Specialty and beauty stores offer a wide range of products under one roof. This segment is anticipated to hold a significant market share in terms of revenue. These stores offer discounts and other benefits, which is expected to bode well for the growth
  • Asia Pacific held the largest market share owing to large female population and rising disposable income. North America, on the other hand, accounted for a considerable market share due to innovation and product diversity coupled with high awareness
  • Some of the key market players are Glenmark, Lil-Lets UK Ltd., Procter & Gamble; Ontex; Natracare Bodywise, Unicharm Corporation, and Kimberly-Clark Corporation (KCWW) among others. Most companies engage in business collaborations to increase product penetration.

Wednesday, 6 March 2019

Hematology Diagnostics Market by Department, Enterprise, Delivery Mode, Vendor & End User 2018

The global hematology diagnostics market size is expected to reach USD 9.39 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 5.85% over the forecast period. Increasing prevalence of blood disorders coupled with adoption of automated testing processes are projected to propel the market growth.\

Automation of hematology diagnostics process have led to reduced turnaround time thereby accelerating the overall treatment regimen. Furthermore, automation has also led to reduced administrative errors and overall costs of diagnostic tests. Thus, it is expected to boost growth of the hematology testing market in the forthcoming years.
Dominance of hematology analyzers can be attributed to the presence of fully-automated analyzers which are objective, have high-throughput, and are cost-effective. Furthermore, these hematology analyzers can also detect atypical results and can improve measurable parameters such as red cell distribution width, platelet distribution, Reticulocyte (RET) counts, and nucleated red cells counts.
The advent of Point-Of-Care (PoC) hematology testing devices has led to improved diagnostic and patient outcomes. These devices are user-friendly and are available for use outside the hospital settings. This is anticipated to increase the acceptability and accessibility of hematology testing which, in turn, is anticipated to propel market growth.
Product recall and intense market competition leading to price wars are anticipated to hinder market growth. In 2018, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes owing to chemical interference with certain tests. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA), thereby indicating that the use of these devices may cause serious injuries or death. Such product recalls can negatively affect the market growth.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the report suggest:
  • Consumables emerged as the largest segment owing to increasing testing and diagnosis of blood disorders
  • Diagnostic labs segment is projected to expand at a lucrative CAGR over the forecast period owing to high prevalence of blood disorders
  • North America held the dominant market share in 2017 owing to favorable reimbursement scenario and presence of sophisticated technological facilities
  • Asia Pacific is projected to witness swift growth during the forecast period owing to the rising healthcare expenditure coupled with focus on quality healthcare infrastructure
  • Few of the key players in hematology testing market include Beckman Coulter, Inc.;Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Siemens Healthineers; Mindray Medical International Limited; and Sysmex Corporation.

Ophthalmology PACS Market Analysis by Players, Size, End-Use, Share Between 2018-2024

The global ophthalmology PACS market size is expected to reach USD 170.96 million by 2025, according to a new report by Grand View Research, Inc. It is projected to witness a CAGR of 6.5% during the forecast period and is driven by rising adoption of Electronic Health Record (EHR) and Electronic Medical Records (EMR) solutions globally. Moreover, rising prevalence of eye diseases, such as cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy, is expected to fuel demand for ophthalmology PACS in near future. The Department of Ophthalmology of National University of Singapore conducted a study in collaboration with National University Health System, Singapore and South Central Asia. According to this study, the number of glaucoma cases diagnosed in 2013 was 17.06 million, which is anticipated to reach around 32.9 million by 2040.

Product development, geographical expansion and M&A are some sustainability strategies adopted by major companies in this market. For instance, in August 2017, Carl Zeiss Meditec Inc., acquired Veracity Innovations, LLC, a U.S.-based medical software company that delivers cloud-based platforms to maximize clinical performance and work efficiency. These platforms help ophthalmologists in delivering personalized technology-enabled care to their patients. The acquisition is intended to expand the former company’s eye care-based digital solutions portfolio. The company is also focusing on expanding the business in Asia Pacific owing to larger patient pool in this region.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the study suggest:
  • Increasing cases of ophthalmic diseases, lack of skilled ophthalmologists, and growing usage of teleophthalmology solutions in developed countries are the factors driving the market
  • According to BrightFocus Foundation’s survey, prevalence of Age-related Macular Degeneration (AMD) is anticipated to rise up to 22 million by 2040. This is also likely to boost market growth
  • Cloud-based PACS is anticipated to register lucrative growth during the forecast period owing to features, such as interoperability and mutual performance, privacy and security, reduced errors, and improved quality
  • North America held the major share of the market in 2017 due to increased ophthalmic disease burden and healthcare expenditure by public and private firms in this region
  • Asia-Pacific is anticipated to register the highest CAGR during forecast period due to rising prevalence of glaucoma coupled with high demand for an effective diagnostic solution
  • Carl Zeiss Meditec AG; Topcon Corp.; Merge Healthcare, Inc. are the major companies in the global ophthalmology PACS market
  • Most of these companies are focusing on technological advancements, M&A, and R&D as part of their business expansion strategies

Tuesday, 5 March 2019

U.S. Craniomaxillofacial (CMF) Devices/System Market Future Demand, Growth Analysis To 2018 – 2025

The U.S. craniomaxillofacial (CMF) devices/systems market size is poised to reach USD 1.62 billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 6.9% during the forecast period. Increasing demand for cranial and facial surgeries is poised to drive the market over the forecast period.

Increasing incidence of sports injuries and road accidents due to industrialization and urbanization has also been providing an upthrust to the U.S. craniomaxillofacial devices market. According to the Wimbledon Clinics Report in 2015, kickboxing caused 2.5 facial injuries per hour and the rate was higher than other combat sports.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the report suggest:
  • Surging demand for minimally invasive surgeries is projected to boost the demand for craniomaxillofacial devices in the U.S. during the forecast period
  • Temporomandibular joint replacement is anticipated to post the highest CAGR over the forecast period, owing to increasing incidence of trauma related to sports injuries and cranial fractures
  • Metallic CMF implants accounted for the largest revenue share in 2017, owing to increasing use of metal 3D implants manufacturing
  • Bioabsorbable material is estimated to register a lucrative CAGR of 7.3% during the same period due to ease with which they assimilate in human body. The other advantages include ability to transfer gradual load to healing tissues and radiolucency
  • Plastic surgeries are expected to show steady growth during the same period, due to burgeoning popularity of the facial augmentation procedure and growing awareness regarding use of CMF devices. According to the American Society of Plastic Surgeons (ASPS), USD 16.0 billion were spent on cosmetic surgeries in 2016
  • Favorable government policies supporting orthognathic surgeries are also likely to stoke the growth of the market
  • Key companies operating in the U.S. craniomaxillofacial devices market are Stryker Corporation; Medtronic Plc; Zimmer-Biomet Inc.; and Medartis AG.
Grand View Research has segmented the U.S. craniomaxillofacial devices market on the basis of product, material, and application:
U.S. Craniomaxillofacial Devices Product Outlook (Revenue, USD Million, 2014 - 2025)
  • Cranial Flap Fixation
  • CMF Distraction
  • Temporomandibular joint replacement
  • Thoracic fixation
  • Bone Graft Substitute
  • MF plate and screw fixation

Plasma Protein Therapeutic Market Key Players, Competitive Strategies, Regional Analysis Forecast 2025

The global plasma protein therapeutics market size is expected to reach USD 33.15 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 4.8% over the forecast period. The growth can be attributed to high prevalence of bleeding and other rare disorders, rising investment in R&D, and increasing use of plasma-derived products in neurology and other therapeutic indications.

Plasma-derived proteins are primarily used as replacement therapies to treat chronic, rare diseases. Patients that rely on these medications require regular injections or infusions throughout their lives. While there are more than 250 products derived from plasma, key players generally rely on Immunoglobulin (IG), albumin, and factor VIII to drive sales and profitability.
Over the past decade, the plasma protein therapeutics market has grown lucratively with immunoglobulin capturing the major market share. Demand for plasma derived-products is driven by rising disease prevalence, geriatric population, and improved access to drugs in emerging markets. Approvals of new plasma-derived therapies are anticipated to further fuel the demand. Developing countries such as China and Brazil offer new investment avenues to the global market giants.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the report suggest:
  • Germany leads the European market, supported by high demand for blood components, presence of key players, large addressable population, and rising disease prevalence
  • Demand for immunoglobulin is expected to continue rising owing to prevalence of primary immunodeficiencies, usage in new indications, and ease of administration
  • Non-plasma based recombinant therapies are likely to compete with plasma-derived products in the factor VIII market
  • Asia Pacific is expected to exhibit high growth over the forecast period fueled by increasing healthcare expenditure, presence of a large number patients. improved ratio of patients suffering from disease and patients receiving treatment, low-cost production of drugs, and improvement in diagnostic technology.
  • Major players operating in the plasma protein therapeutics market include CSL Behring, Grifols, S.A., Shire Plc, Octapharma AG, Biotest AG, and Kedrion S.P.A. Regional expansion, broad product portfolio, and merger & acquisitions are chief strategic undertakings adopted by key players.

Friday, 1 March 2019

Moist Wound Dressings Industry Grow Exponentially During The Forecast Period 2018 to 2025

The global moisture wound dressing market size is expected to reach USD 5.45 billion by 2025, according to a new report by Grand View Research, Inc. The market is projected to witness a CAGR of 5.6% over the forecast period. Key factor driving the market are increasing cases of acute and chronic wounds, such as surgical, diabetic and traumatic wounds, lacerations, and diabetic ulcers. As per estimates provided by Elsevier, about 300 million acute wound injuries occur per year.

Ongoing R&D in the healthcare field is leading to the development of new products. For instance, the advent of keratin-based wound care products. These products facilitate wound re-epithelialization but also forms part of dressings and aid in wound healing as the keratin matrix in them gets absorbed in the wound eliminating the need to change the dressing. Furthermore, introduction of novel therapies, such as electromagnetic therapy, electrical stimulation, nanotechnology, and the use of silver and other combination dressings are boosting the market.
These advancements ensure better wound care during any trauma, thereby supporting the market growth. Similarly, new products in pipeline are anticipated to augment the market development over the forecast period. For instance, Researchers in Massachusetts Institute of Technology in U.S. and University of Nebraska-Lincoln, Harvard Medical School have developed a bandage that provides precise and scheduled drug delivery, which can be customized as per requirement. Such innovations are expected to create growth opportunities for the market players.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the report suggest:
  • On the basis of product, foam wound dressings account for the largest share owing to their ability to maintain moisture, which facilitates healing process
  • Surgical application segment accounts for the largest market share due to increasing number of surgical procedures being performed; as all types of wound dressings are required during surgeries
  • Southeast Asia moist wound dressings market is expected to witness significant development as the region holds potential growth opportunities due to the presence of, emerging nations like Indonesia and Thailand
  • The diabetic ulcer segment is anticipated to witness the highest CAGR during the forecast period on account of increasing prevalence of the disease and related complications
  • Key companies in the market are 3M Healthcare; Coloplast A/S; Medline Industries, Inc.; Cardinal Health, Inc.; B. Braun Melsungen AG; Smith & Nephew PLC; ConvaTec Group PLC; Derma Sciences, Inc.; and Systagenix Wound Management Ltd.

Antibiotic Resistance Market Exhibit Scenario and the Development Prospects 2018-2025

The global antibiotic resistance market size is estimated to reach USD 12.07 billion by 2025. According to a new report by Grand View Research, Inc., it is anticipated to post a CAGR of 5.6% during the forecast period. Rising burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been driving the market.

Biotech companies that are developing therapies for antibiotic-resistant infections include Melinta Therapeutics, Achaogen, and Nabriva Therapeutics. On the other hand, majority of large pharmaceutical companies don’t find this market lucrative enough due to slower growth in revenues for marketed drugs and lower return on investments. For instance, Novartis recently discontinued development of its antibacterial drugs for antibiotic resistance.
Manufacturers can obtain the Qualified Infectious Disease Product (QIDP) designation, which escalates the clinical review process for antibacterial therapies targeting high priority pathogens. The QIDP designation enables faster access to targeted agents and was introduced under the GAIN (Generating Antibiotic Incentives Now) Act, passed in 2012 as an extension to the U.S. FDA Safety and Innovation Act. The legislation aims to encourage the development of novel therapies for growing burden and severity of infections with antibiotic resistance.
 To request a sample copy or view summary of this report, click the link below: 

Further key findings from the report suggest:
  • In 2017, the market by cUTI disease registered significant sales due to elevated rate of resistance in extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae and P. aeruginosa strains
  • The combination therapies segment, which includes fixed-dose combinations of beta lactams and beta lactamase inhibitors, is projected to witness the fastest growth rate over the forecast period
  • Infections due to E. coli pathogens that are ESBL-producing and carbapenem-resistant led in terms of sales revenue in 2017 due to high treatment cost
  • On the geographical front, North America was the dominant revenue contributor in the market in 2017. Improving reimbursement scenario with new technology add-on payment provision is promoting the use of novel products in this region
  • Among pharmaceutical companies, Merck, Allergan, and Pfizer were the key players with top-selling drugs in the antibiotic resistance market in 2017.